Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jan 07, 2026
AI’s Verdict: Rocket Lab USA (RKLB) vs. Planet Labs (PL) - High-Growth Potential in 2026

AI’s Verdict: Rocket Lab USA (RKLB) vs. Planet Labs (PL) - High-Growth Potential in 2026

Key Takeaways

An AI-driven comparison between Rocket Lab USA (RKLB) and Planet Labs (PL) identifies Rocket Lab as the more compelling investment heading into 2026. The analysis highlights RKLB’s vertically integrated space services and consistent launch performance, which position the company to benefit from rising demand for satellite deployment and space infrastructure. While Planet Labs leads in Earth observation imagery and data analytics, Rocket Lab’s proven launch cadence and expanding service portfolio offer greater scalability and growth potential.

In 2025, Rocket Lab completed 21 launches with a 100% mission success rate, reinforcing its reputation for reliability. Looking ahead to 2026, RKLB is projected to grow revenue by approximately 40% to $500 million, with earnings per share reaching $0.30. Planet Labs is expected to deliver steadier growth, with revenue rising about 20% to $300 million and EPS near $1.20. Price forecasts reflect these differing profiles: RKLB is projected to average $68 by the end of 2026, with upside reaching $90, while PL is expected to average $19, with highs near $22. Although Rocket Lab trades at a higher forward valuation multiple, that premium reflects its faster growth trajectory and expanding role in the space economy.

Tickeron’s AI-powered trading bots further tilt the balance toward RKLB. Strategies focused on Rocket Lab have produced annualized returns of up to 279%, supported by win rates around 75%, outperforming PL-focused strategies that average closer to 200%. Overall, AI-driven analysis favors Rocket Lab for its mission reliability, expansion potential, and superior performance in both fundamentals and algorithmic trading.

Products and Services: Rocket Lab USA vs. Planet Labs

Rocket Lab USA and Planet Labs both operate within the space industry, but their business models and core offerings differ significantly. Rocket Lab focuses on launch services and spacecraft manufacturing, while Planet Labs specializes in satellite imagery and geospatial data analytics. As of early 2026, both serve government, commercial, and research customers, but with distinct value propositions.

Rocket Lab provides end-to-end space solutions, spanning launch services, spacecraft design, satellite manufacturing, and component supply. Its Electron rocket is optimized for small satellite missions and achieved 21 successful launches in 2025 alone. The company is also preparing to debut Neutron, a medium-lift launch vehicle targeted for mid-2026. Beyond launches, Rocket Lab offers mission management, payload integration, and in-space operations, enabling customers to move from concept to orbit within a single ecosystem. In 2025, RKLB secured an $816 million contract for satellite construction and expanded U.S.-based investments tied to national security and advanced manufacturing initiatives.

Planet Labs, by contrast, focuses on collecting and analyzing Earth observation data. Its satellite constellation delivers frequent global imagery, supporting applications in agriculture, defense, climate monitoring, and infrastructure analysis. Key offerings include PlanetScope for daily monitoring and SkySat for high-resolution imagery, supported by AI-powered analytics tools such as Planet Insights. In 2025, Planet Labs reported third-quarter revenue of $81.3 million, representing 33% year-over-year growth, and raised its full-year 2026 revenue guidance to approximately $300 million. The company generates revenue primarily through subscriptions and data licensing agreements.

While Planet Labs excels in turning satellite imagery into actionable intelligence, Rocket Lab stands out for providing the physical infrastructure that enables space missions in the first place. Financially, Planet Labs’ fiscal 2025 revenue slightly exceeded Rocket Lab’s, but Rocket Lab’s expanding contract backlog and launch capabilities suggest stronger upside potential over the medium term.

AI Trading Performance: Tickeron Bots on RKLB and PL

Tickeron’s AI Trading Bot use advanced financial learning models to analyze real-time price data, sentiment, and technical patterns. These systems deploy strategies such as momentum trading, hedging, and volatility capture, which are particularly effective in fast-evolving sectors like space technology.

For Rocket Lab, the bots have been especially successful in capitalizing on launch announcements, contract awards, and program milestones. Top-performing strategies delivered annualized returns of up to 279%, with win rates around 75%. Multi-agent strategies achieved gains exceeding 170% over shorter periods, while volatility-focused approaches produced outsized returns on leveraged trades. Ensemble models further improved risk-adjusted performance by reducing drawdowns.

Planet Labs-focused bots also performed well but showed lower peak upside. Average annualized returns were closer to 200%, with win rates near 70%. Strategies tended to benefit from steady subscription growth and earnings-related catalysts but lacked the explosive momentum often seen in Rocket Lab trades.

In direct comparison, RKLB-focused strategies outperformed PL by roughly 30–50%, driven by stronger growth signals and higher Sharpe ratios—an advantage heading into a potentially dynamic space market in 2026.

2026 Price Outlook for RKLB and PL

Price forecasts for 2026 reflect continued optimism across the space sector, with Rocket Lab positioned as a primary growth beneficiary. RKLB is projected to average $68 by year-end, with a trading range between $47 and $90, driven by Neutron’s anticipated debut, expanding launch cadence, and growing manufacturing revenue. Quarterly estimates suggest a gradual rise from $60 in Q1 to $68 by Q4.

Planet Labs is expected to average $19 in 2026, with a range from $12 to $22, supported by continued demand for Earth observation data and analytics. Quarterly projections indicate steady progress from $17 in Q1 to $19 by Q4. Both outlooks assume stable industry conditions, but Rocket Lab’s contract-driven growth provides greater upside potential.

Final Verdict: RKLB or PL?

From an AI-driven perspective, Rocket Lab USA emerges as the preferred choice for 2026. Its reliable launch record, vertically integrated business model, and expanding role in satellite deployment and space infrastructure give it a clear advantage over Planet Labs’ more narrowly focused data-centric model. While Planet Labs offers dependable, subscription-based revenue tied to Earth observation, its growth profile is more limited.

With RKLB projected to average $68 in 2026 and supported by AI trading strategies delivering returns of up to 279%, Rocket Lab stands out as the more dynamic and scalable space technology investment. Investors seeking exposure to geospatial data may still favor PL, but those prioritizing innovation, mission success, and high-growth potential are likely to align more closely with Rocket Lab.

Disclaimers and Limitations

Related Ticker: RKLB, PL

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


RKLB's RSI Oscillator recovers from oversold territory

The RSI Oscillator for RKLB moved out of oversold territory on September 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In 29 of the 32 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on RKLB as a result. In 72 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for RKLB just turned positive on September 15, 2026. Looking at past instances where RKLB's MACD turned positive, the stock continued to rise in 41 of 44 cases over the following month. The odds of a continued upward trend are 90%.

RKLB moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for RKLB crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +6.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where RKLB advanced for three days, in 260 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 55 cases where RKLB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RKLB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

RKLB broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RKLB entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. RKLB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock slightly better than average.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.210) is normal, around the industry mean (6.305). P/E Ratio (27.472) is within average values for comparable stocks, (58.116). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (48.309) is also within normal values, averaging (18.330).

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 38.94B. The market cap for tickers in the group ranges from 4.49 to 1.92T. SPCX holds the highest valuation in this group at 1.92T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was -1%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -11%. SPCX experienced the highest price growth at 18%, while PUSA experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 45
P/E Growth Rating: 70
Price Growth Rating: 62
SMR Rating: 77
Profit Risk Rating: 76
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
RKLB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry AerospaceDefense

Industry
N/A
Address
3881 McGowen Street
Phone
+1 714 465-5737
Employees
2600
Web
https://www.rocketlabusa.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
AI’s Verdict: Rocket Lab USA (RKLB) vs. Planet Labs (PL) - High-Growth Potential in 2026